Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia

The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02872818

Enrollment

Registered

2016-08-19

Start date

2014-10-31

Completion date

2015-03-31

Last updated

2016-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apoptotic Signal Pathways in Endometrial Hyperplasia

Keywords

Apoptotic signal pathway, Survivin, Bcl-2, Bax, c-Myc, Caspase-9, endometrial hyperplasia, endometrium cancer

Brief summary

The purpose of the study is to determine apoptotic signaling pathways such as Survivin, Bcl-2, Bax, c-Myc and caspase-9 expression levels in rats model with iatrogenic endometrial hyperplasia after metformin and medroxyprogesterone acetate administration.

Interventions

DRUG17β estradiol hemihydrate

4mg/kg/day for 20 days

DRUGMetformin

50 mg/kg/day last 10 days

DRUGmedroxyprogesterone acetate

1mg/kg/day last 10 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

8 Weeks to 10 Weeks

Healthy volunteers

Inclusion criteria

Forty-eight weeks old female Wistar-Albino rats, weighting between 180 and 260 g

Exclusion criteria

. We have no

Design outcomes

Primary

Measure	Time frame
Survivin Gene Expression Levels in Rat Uterine Tissue	4 months
Bcl-2 Gene Expression Levels in Rat Uterine Tissue	4 months
Bax Gene Expression Levels in Rat Uterine Tissue	4 months
c-Myc Gene Expression Levels in Rat Uterine Tissue	4 months
Caspase-9 Expression Levels in Rat Uterine Tissue	4 months

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026